Currently, improved PEGylated asparaginase with reduced hyposensitivity and a longer half-life is widely used in pediatric ALL patients (Avramis and Tiwari, 2006; Zhang et al., 2020; Riley et al., 2021). Here, ASPG is linked to acute lymphoblastic leukemia.